. 2016 Apr 21;6:24267. doi: 10.1038/srep24267

Table 1. HSP27 and 70 expression in TETs and analysis of clinicopathologic characteristics.

Clinicopathologic characteristics		HSP expression in TETs
		Cyto HSP27		Cyto HSP70		Nucl HSP70
		n	mean ± SEM	n	mean ± SEM	n	mean ± SEM
WHO	A	16	2.63 ± 0.1	16	2.0 ± 0.2	16	2.44 ± 0.2
	AB	14	2.54 ± 0.1	14	2.5 ± 0.2	14	2.61 ± 0.2
	B1	10	2.30 ± 0.2	11	1.55 ± 0.4	11	1.86 ± 0.3
	B2	21	2.79 ± 0.1	21	2.29 ± 0.2	21	2.60 ± 0.2
	B3	17	2.85 ± 0.1	17	2.0 ± 0.1	17	2.38 ± 0.2
	TC	15	2.93 ± 0.1	15	2.1 ± 0.2	15	2.23 ± 0.3
	MNT	4	3.0 ± 0.0	4	2.5 ± 0.3	4	2.5 ± 0.3
	TNET	3	0.5 ± 0.3	3	1.33 ± 0.4	3	0.33 ± 0.3
p-value			< 0.001^a		0.061^a		0.003^a
Masaoka-Koga Stage	I	23	2.52 ± 0.1	23	2.30 ± 0.1	23	2.59 ± 0.1
	II	46	2.64 ± 0.1	47	2.17 ± 0.1	47	2.39 ± 0.1
	III	15	2.67 ± 0.2	15	1.97 ± 0.2	15	2.37 ± 0.3
	IV	16	2.63 ± 0.2	16	1.78 ± 0.3	16	1.75 ± 0.3
p-value			0.770^a		0.261^a		0.037^a

HSP27 and 70 were strongly expressed in all thymomas and TCs but weak or absent in TNETs. Strongest nuclear HSP70 expression was found in non-invasive TETs (Masaoka-Koga stage I), whereas the weakest expression was found in metastatic TETs (Masaoka-Koga stage IV). Paraneoplastic MG had no significant difference on HSP27 and 70 staining intensities in TETs. HSP27, Heat Shock Protein 27; HSP70, Heat Shock Protein 70; n, number; Cyto, cytoplasmic expression; Nucl., nuclear expression; WHO, World Health Organization; TC, Thymic Carcinoma; MNT, Micronodular Thymoma; TNET, Thymic Neuroendocrine Tumor; MG, Myasthenia Gravis; SEM, standard error of the mean.

^aOne-way Anova.